<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The US FDA-approved thalidomide for the treatment of <z:hpo ids='HP_0011010'>chronic</z:hpo> recurrent/severe <z:hpo ids='HP_0010783'>erythema</z:hpo> nodosum leprosum </plain></SENT>
<SENT sid="1" pm="."><plain>Thalidomide is also useful in many other inflammatory dermatological conditions where patients have exhausted other treatment options </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The beneficial and adverse clinical effects of thalidomide were studied in 25 patients suffering from different inflammatory dermatological conditions that were poorly controlled with conventional therapies </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Thalidomide was found to be effective in various inflammatory <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">dermatological diseases</z:e> other than <z:hpo ids='HP_0011010'>chronic</z:hpo> recurrent <z:hpo ids='HP_0010783'>erythema</z:hpo> nodosum leprosum such as <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease, disseminated and hypertrophic <z:hpo ids='HP_0007417'>discoid lupus erythematosus</z:hpo>, erosive <z:e sem="disease" ids="C0023646" disease_type="Disease or Syndrome" abbrv="">lichen planus</z:e>, <z:hpo ids='HP_0007417'>discoid lupus erythematosus</z:hpo>-<z:e sem="disease" ids="C0023646" disease_type="Disease or Syndrome" abbrv="">lichen planus</z:e> overlap, <z:hpo ids='HP_0011107'>recurrent aphthous stomatitis</z:hpo> and <z:e sem="disease" ids="C0263353" disease_type="Disease or Syndrome" abbrv="">prurigo nodularis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002625'>Deep vein thrombosis</z:hpo> due to thalidomide occurred in 20% of these patients and appears to be a significant side effect </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Thalidomide appears promising in a number of inflammatory dermatological conditions and will probably find new usages in future </plain></SENT>
<SENT sid="6" pm="."><plain>The treating physicians need to be wary of the thrombo-embolic complications due to thalidomide especially when <z:chebi fb="1" ids="24261">glucocorticoids</z:chebi> or other chemotherapeutic agents such as <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="175901">gemcitabine</z:chebi>, <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> or <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>-<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> pulse therapy are being used concomitantly, and in patients of metastatic <z:hpo ids='HP_0005584'>renal carcinoma</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> receiving thalidomide/chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>Antiphospholipid or anticardiolipin antibodies appear to be other possible risk factors for this complication </plain></SENT>
</text></document>